RBC Capital upgrades Regenxbio to Outperform, sees positive risk-reward

As previously reported, RBC Capital upgraded Regenxbio to Outperform from Sector Perform with a price target of $35, up from $20. The firm is “cautious” on the ocular programs, but also “impressed” by the company’s recent execution, and believes that Duchenne updates should drive the stock higher from here, the analyst tells investors in a research note. At $0.8B enterprise value and with a “busy calendar”, risk/reward for Regenxbio is skewed favorably, RBC added.